Klaviyo Quarterly Balance Sheets Chart
Quarterly
|
Annual
Klaviyo Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|---|---|---|---|
| assets | ||||||||
| current assets: | ||||||||
| cash and cash equivalents | 935,516,000 | 888,432,000 | 881,473,000 | 826,742,000 | 793,555,000 | 755,827,000 | 738,562,000 | 723,415,000 |
| restricted cash | 375,000 | 417,000 | 402,000 | 393,000 | 409,000 | 386,000 | ||
| accounts receivable | 58,843,000 | 53,909,000 | 43,095,000 | 34,464,000 | 29,226,000 | 23,241,000 | 23,076,000 | 17,380,000 |
| deferred contract acquisition costs, current | 25,070,000 | 22,995,000 | 20,544,000 | 19,026,000 | 18,031,000 | 17,177,000 | 15,198,000 | 14,161,000 |
| prepaid expenses and other current assets | 41,642,000 | 41,903,000 | 34,262,000 | 35,568,000 | 31,149,000 | 29,804,000 | 26,244,000 | 26,010,000 |
| total current assets | 1,061,071,000 | 1,007,239,000 | 979,749,000 | 916,217,000 | 872,363,000 | 826,442,000 | 803,489,000 | 781,352,000 |
| property and equipment | 56,677,000 | 51,746,000 | 48,200,000 | 45,189,000 | 44,367,000 | 42,786,000 | 43,450,000 | 42,730,000 |
| right-of-use assets | 86,592,000 | 90,816,000 | 42,917,000 | 30,141,000 | 32,073,000 | 34,684,000 | 36,987,000 | 39,506,000 |
| deferred contract acquisition costs, non-current | 36,799,000 | 34,469,000 | 32,527,000 | 30,007,000 | 26,696,000 | 24,507,000 | 23,177,000 | 20,687,000 |
| restricted cash, non-current | 738,000 | 739,000 | 739,000 | 739,000 | 672,000 | 657,000 | 686,000 | 648,000 |
| prepaid marketing expense | 143,098,000 | 148,222,000 | 153,346,000 | 158,471,000 | 163,595,000 | 168,720,000 | 173,844,000 | 178,968,000 |
| other non-current assets | 12,907,000 | 14,080,000 | 15,830,000 | 12,435,000 | 10,072,000 | 10,600,000 | 7,417,000 | 7,533,000 |
| total assets | 1,397,882,000 | 1,347,311,000 | 1,273,308,000 | 1,193,199,000 | 1,149,838,000 | 1,108,396,000 | 1,089,050,000 | 1,071,424,000 |
| liabilities and stockholders’ equity | ||||||||
| current liabilities: | ||||||||
| accounts payable | 22,879,000 | 14,290,000 | 14,579,000 | 11,351,000 | 9,418,000 | 8,464,000 | 13,597,000 | 9,738,000 |
| accrued expenses | 89,563,000 | 83,772,000 | 99,828,000 | 64,917,000 | 62,404,000 | 65,134,000 | 62,838,000 | 62,602,000 |
| lease liabilities, current | 19,086,000 | 18,575,000 | 20,989,000 | 13,126,000 | 13,009,000 | 13,625,000 | 14,081,000 | 14,449,000 |
| deferred revenue | 82,711,000 | 76,187,000 | 64,497,000 | 52,932,000 | 46,782,000 | 42,519,000 | 40,100,000 | 32,866,000 |
| total current liabilities | 214,239,000 | 192,824,000 | 199,893,000 | 142,326,000 | 131,613,000 | 129,742,000 | 130,616,000 | 119,655,000 |
| lease liabilities, non-current | 80,101,000 | 84,115,000 | 32,449,000 | 29,333,000 | 32,069,000 | 34,759,000 | 37,498,000 | 40,016,000 |
| other non-current liabilities | 6,790,000 | 6,440,000 | 6,979,000 | 6,799,000 | 6,656,000 | 6,443,000 | 6,159,000 | 6,409,000 |
| total liabilities | 301,130,000 | 283,379,000 | 239,321,000 | 178,458,000 | 170,338,000 | 170,944,000 | 174,273,000 | 166,080,000 |
| stockholders’ equity | ||||||||
| preferred stock: 0.001 par value; 100,000,000 shares authorized; 0 and 0 shares issued and outstanding at june 30, 2025, and december 31, 2024, respectively. | ||||||||
| series a common stock: 0.001 par value; 3,000,000,000 shares authorized; 116,877,930 and 88,956,301 shares issued and outstanding at june 30, 2025, and december 31, 2024, respectively. | 117,000 | |||||||
| series b common stock: 0.001 par value; 350,000,000 shares authorized; 182,757,254 and 183,801,332 shares issued and outstanding at june 30, 2025, and december 31, 2024, respectively. | 183,000 | |||||||
| additional paid-in capital | 1,980,007,000 | 1,922,930,000 | 1,878,899,000 | 1,832,684,000 | 1,796,100,000 | 1,749,113,000 | 1,713,560,000 | 1,677,833,000 |
| accumulated deficit | -883,555,000 | -859,274,000 | -845,185,000 | -818,212,000 | -816,867,000 | -811,925,000 | -799,043,000 | -772,748,000 |
| total stockholders’ equity | 1,096,752,000 | 1,063,932,000 | 1,033,987,000 | 1,014,741,000 | 979,500,000 | 937,452,000 | 914,777,000 | 905,344,000 |
| total liabilities and stockholders’ equity | 1,397,882,000 | 1,347,311,000 | 1,273,308,000 | 1,193,199,000 | 1,149,838,000 | 1,108,396,000 | ||
| preferred stock: 0.001 par value; 100,000,000 shares authorized; 0 and 0 shares issued and outstanding at march 31, 2025, and december 31, 2024, respectively. | ||||||||
| series a common stock: 0.001 par value; 3,000,000,000 shares authorized; 94,574,036 and 88,956,301 shares issued and outstanding at march 31, 2025, and december 31, 2024, respectively. | 95,000 | |||||||
| series b common stock: 0.001 par value; 350,000,000 shares authorized; 180,983,334 and 183,801,332 shares issued and outstanding at march 31, 2025, and december 31, 2024, respectively. | 181,000 | |||||||
| preferred stock: 0.001 par value; 100,000,000 and 100,000,000 shares authorized; 0 and 0 shares issued; 0 and 0 shares outstanding at december 31, 2024 and 2023, respectively. | ||||||||
| series a common stock: 0.001 par value; 3,000,000,000 and 3,000,000,000 shares authorized; 88,956,301 and 40,841,834 shares issued and outstanding at december 31, 2024 and 2023, respectively. | 89,000 | |||||||
| series b common stock: 0.001 par value; 350,000,000 and 350,000,000 shares authorized; 183,801,332 and 218,524,009 shares issued and outstanding at december 31, 2024 and 2023, respectively. | 184,000 | |||||||
| preferred stock: 0.001 par value; 100,000,000 shares authorized; 0 and 0 shares issued and outstanding at september 30, 2024, and december 31, 2023, respectively. | ||||||||
| series a common stock: 0.001 par value; 3,000,000,000 shares authorized; 78,478,265 and 40,841,834 shares issued; 78,478,265 and 40,841,834 shares outstanding at september 30, 2024, and december 31, 2023, respectively. | 78,000 | |||||||
| series b common stock: 0.001 par value; 350,000,000 shares authorized; 190,696,188 and 218,524,009 shares issued; 190,696,188 and 218,524,009 shares outstanding at september 30, 2024, and december 31, 2023, respectively. | 191,000 | |||||||
| preferred stock: 0.001 par value; 100,000,000 shares authorized; 0 and 0 shares issued and outstanding at june 30, 2024, and december 31, 2023, respectively. | ||||||||
| series a common stock: 0.001 par value; 3,000,000,000 shares authorized; 72,510,738 and 40,841,834 shares issued; 72,510,738 and 40,841,834 shares outstanding at june 30, 2024, and december 31, 2023, respectively. | 73,000 | |||||||
| series b common stock: 0.001 par value; 350,000,000 shares authorized; 194,081,029 and 218,524,009 shares issued; 194,081,029 and 218,524,009 shares outstanding at june 30, 2024, and december 31, 2023, respectively. | 194,000 | |||||||
| preferred stock: 0.001 par value; 100,000,000 shares authorized; 0 and 0 shares issued and outstanding at march 31, 2024, and december 31, 2023, respectively. | ||||||||
| series a common stock: 0.001 par value; 3,000,000,000 shares authorized; 70,065,833 and 40,841,834 shares issued; 70,065,833 and 40,841,834 shares outstanding at march 31, 2024, and december 31, 2023, respectively. | 70,000 | |||||||
| series b common stock: 0.001 par value; 350,000,000 shares authorized; 193,969,875 and 218,524,009 shares issued; 193,969,875 and 218,524,009 shares outstanding at march 31, 2024, and december 31, 2023, respectively. | 194,000 | |||||||
| liabilities, redeemable common stock, and stockholders’ equity | ||||||||
| redeemable common stock | ||||||||
| redeemable common stock, 0.001 par value, 0 and 64,046,223 shares issued and outstanding at december 31, 2023 and 2022, respectively. | ||||||||
| preferred stock: 0.001 par value; 100,000,000 and 0 shares authorized; 0 and 0 shares issued; 0 and 0 shares outstanding at december 31, 2023 and 2022, respectively. | ||||||||
| series a common stock: 0.001 par value; 3,000,000,000 and 0 shares authorized; 40,841,834 and 0 shares issued; 40,841,834 and 0 shares outstanding at december 31, 2023 and 2022, respectively. | 41,000 | |||||||
| series b common stock: 0.001 par value; 350,000,000 and 316,000,000 shares authorized; 218,524,009 and 170,882,108 shares issued; 218,524,009 and 170,855,313 shares outstanding at december 31, 2023 and 2022, respectively. | 219,000 | |||||||
| total liabilities, redeemable common stock, and stockholders’ equity | 1,089,050,000 | 1,071,424,000 | ||||||
| redeemable common stock, 0.001 par value, 0 and 64,046,223 shares outstanding at september 30, 2023, and december 31, 2022, respectively. | ||||||||
| preferred stock: 0.001 par value; 100,000,000 and 0 shares authorized; 0 and 0 shares issued and outstanding at september 30, 2023, and december 31, 2022, respectively. | ||||||||
| series a common stock: 0.001 par value; 3,000,000,000 and 0 shares authorized; 32,740,767 and 0 shares issued; 32,740,767 and 0 shares outstanding at september 30, 2023, and december 31, 2022, respectively. | 33,000 | |||||||
| series b common stock: 0.001 par value; 350,000,000 and 316,000,000 shares authorized; 225,557,191 and 170,882,108 shares issued; 225,557,191 and 170,855,313 shares outstanding at september 30, 2023, and december 31, 2022, respectively. | 226,000 |
We provide you with 20 years of balance sheets for Klaviyo stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Klaviyo. Explore the full financial landscape of Klaviyo stock with our expertly curated balance sheets.
The information provided in this report about Klaviyo stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.